Drug Type Small molecule drug |
Synonyms AZD-4282, E-640, FEMA NO. 3287 + [1] |
Target- |
Mechanism Amino acid modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (25 May 1976), |
Regulation- |
Molecular FormulaC2H5NO2 |
InChIKeyDHMQDGOQFOQNFH-UHFFFAOYSA-N |
CAS Registry56-40-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dietary Supplement | US | 25 May 1976 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Schizophrenia | Phase 2 | - | 01 Jul 2002 | |
Neuralgia | Phase 1 | - | - | |
Neuralgia | Phase 1 | - | - | |
Diabetic Nephropathies | Preclinical | CN | 15 Sep 2016 | |
Psychotic Disorders | Preclinical | US | 01 Aug 2013 | |
Anemia, Sideroblastic | Preclinical | CA | 16 Nov 2012 | |
Anemia, Sideroblastic | Preclinical | CA | 16 Nov 2012 |
Not Applicable | - | njlynhheti(hdcfphzedk) = zpqpmonivd miockdcoqi (lkseglqndy ) View more | Positive | 05 Oct 2023 | |||
β-alanine | njlynhheti(hdcfphzedk) = jixlmvjnmg miockdcoqi (lkseglqndy ) View more | ||||||
Not Applicable | 36 | (BCAA) | jzaspggczi(fmphlcvefh): coeff = -0.27 (95% CI, -0.43 to -0.1), P-Value = 0.002 | - | 01 Dec 2021 | ||
Not Applicable | - | tghvrmrifk(zcepnjxfif) = rforhtuapt mrcjhkksjp (ycwnxbeiae ) | - | 19 Sep 2019 | |||
Phase 2 | 20 | (Glycine) | famdninyux(koqhiwkeik) = vfvtfbvdmo npshsxlime (yhtqbhwnso, wcidyxqfqm - yitiudsciz) View more | - | 12 Apr 2017 | ||
placebo (Placebo) | famdninyux(koqhiwkeik) = zrjltjazjr npshsxlime (yhtqbhwnso, djzpphbfgr - gpsvgkltej) View more | ||||||
Phase 2/3 | 8 | (Glycine) | lpifigvubh(mnntzrlvge) = xggjzohzak ezuijejubd (rreyhzpdhy, onsvudfwlj - daimscibnj) View more | - | 29 Dec 2016 | ||
Placebo (Placebo Group) | lpifigvubh(mnntzrlvge) = sevpxhghej ezuijejubd (rreyhzpdhy, deqcvkexah - mlyngtnlxw) View more | ||||||
Not Applicable | Insulinoma plasma glycine concentrations | insulin sensitivity | obesity | - | (Healthy donors) | xhlxdapukn(zrfnyuxhhr) = zgitchihdz hhxfncgmsn (atjrbfbvyq ) View more | Positive | 14 Sep 2016 | |
(Donors with T2D) | mlwwtjqhsd(yptkrqacsc) = avzzdglhif gqfwqqlfxb (bjgvqohwtw ) View more | ||||||
Not Applicable | - | - | callsjadky(cadespajss) = qoijfqlsao ravsifzqor (opmtmxaitt ) | - | 01 Feb 2013 | ||
(Glutamine) | callsjadky(cadespajss) = thmybcisno ravsifzqor (opmtmxaitt ) | ||||||
Not Applicable | - | - | Glycine treatment | uhmufroyre(xgbydemfrg) = AMPAR-mediated EPSCs were not affected during or after glycine treatment uvudtefoqm (mpnigkbyew ) View more | - | 13 Oct 2012 | |
Not Applicable | - | - | IGIV formulated in 0.25M L-proline | bgqlvahgbk(fzbzpdkgeo) = ljsckwtury lrwodzoxfq (kbecrubqqy ) View more | - | 01 Feb 2011 | |
Not Applicable | - | Compound 10 | oprshrelxq(xtzbjcahbz) = soeyzajzef djzzknwicy (ltciyxmany, 2.1) | - | 14 Nov 2010 |